All In Biotech

Drug Trial Radar · NCT00401843

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade Versus Velcade Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

307

Actual

Start

Nov 28, 2006

Primary completion

Aug 16, 2011

Study completion Sep 24, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 22, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade). The purpose of Part 2 of the study is to compare the length of progression free survival for those patients given CNTO 328 and bortezomib to those patients given bortezomib alone.

Conditions

  • Multiple Myeloma

Interventions

  • SiltuximabBiological

    Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.

  • BortezomibDrug

    Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.

  • PlaceboDrug

    Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.

  • DexamethasoneDrug

    Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free SurvivalTime frame: Randomization until disease progression or death, which ever occured first (maximum up to 5 years)
  2. Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)Time frame: up to 5 years

Locations

80 sites in 18 countries. Site status is shown where the registry gives one.

  • Site not named

    Greenbrae, California

  • Site not named

    Los Angeles, California

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    New York, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    North Charleston, South Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Madison, Wisconsin

  • Site not named

    Antwerp, Belgium

  • Site not named

    B-8000 Brugge, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Edegem, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Bulgaria, Bulgaria

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Calgary, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Québec, Quebec, Canada

  • Site not named

    Brno, Czechia

  • Site not named

    Hradec Králové, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Grenoble, France

  • Site not named

    Lille Cedex N/a, France

  • Site not named

    Montpellier, France

  • Site not named

    Pierre-Bénite, France

  • Site not named

    Vandœuvre-lès-Nancy, France

  • Site not named

    Aschaffenburg, Germany

  • Site not named

    Essen, Germany

  • Site not named

    Mainz, Germany

  • Site not named

    Münster, Germany

  • Site not named

    Stuttgart, Germany

  • Site not named

    Ulm, Germany

  • Site not named

    Athens, Greece

  • Site not named

    Budapest, Hungary

  • Site not named

    Debrecen, Hungary

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.